01707nas a2200217   4500000000100000008004100001260001600042100001700058700001300075700001600088700001500104700001400119700001400133700001700147245011000164856015300274300001100427490000600438520103100444022001401475       2021                            d  bElsevier BV1 aPerehudoff K1 aDurán C1 aDemchenko I1 aMazzanti V1 aParwani P1 aSuleman F1 ade Ruijter A00aImpact of the European Union on access to medicines in low- and middle-income countries: A scoping review  uhttps://www.sciencedirect.com/science/article/pii/S2666776221001964/pdfft?md5=f9e9982db05fb1997330644a1c0d5136&pid=1-s2.0-S2666776221001964-main.pdf  a1002190 v93 aThis Scoping Review synthesises evidence of the impacts of European Union (EU) law, regulation, and policy on access to medicines in in non-EU low- and middle-income countries (LMICs), and the mechanisms and nature of those impacts. We searched eight scholarly databases and grey literature published between 1995-2021 in four languages. The EU exerts global influence on pharmaceuticals in LMICs in three ways: explicit agreements between EU-LMICs (ex. accession, trade, and economic agreements); LMICs' reliance on EU internal regulation, standards, or methods (ex. market authorisation); ‘soft’ forms of EU influence (ex. research funding, capacity building). This study illustrates that EU policy makers adopt measures with the potential to influence medicines in LMICs despite limited evidence of their positive and/or negative impact(s). The EU's fragmented internal and external actions in fields related to pharmaceuticals reveal the need for principles for global equitable access to medicines to guide EU policy.  a2666-7762